Estrogen Modulates NK and CD8+T Cell Response via the PD-1 PD-L1 Axis Impairing Anti-Tumour Effects of Zoledronic Acid

Published in NPJ Breast Cancer, 2026

Clinical trials in breast cancer have demonstrated reduced recurrence in bone and soft tissue in postmenopausal women following adjuvant treatment with Zoledronic acid (Zol). In contrast however, the same treatment resulted in an increased risk of extra-skeletal recurrence in premenopausal women. The reason for these stark differences has remained unclear, until now preventing thousands of young breast cancer patients from being able to benefit from the life prolonging effects of Zol. Here we demonstrate that Zol induces an anti-tumor response by increasing infiltration of CD8+T, dendritic and NK cells into soft tissue metastases, but only when estrogen concentrations are low. Anti-tumor response to Zol appears to be CD8+T and NK cell-dependent in soft tissue, but only NK cell-dependent in bone. Conversely, estrogen significantly reduces systemic and tumor infiltrating CD8+ and CD4+T cells, increases PD-1 expression on T and NK cells and increases PD-L1 on tumor cells. We propose that estradiol reduces anti-cancer lymphoid cell infiltration into tumors and increases their exhaustion status, preventing Zol-induced activation of T and NK cells. Our data suggests that under premenopausal concentrations of estradiol, anti-tumor response to Zol can be restored by blocking PD-1/PD-L1 interactions, thereby overcoming estrogen driven immune suppression.

Keywords: Breast Cancer; Zoledronic Acid; T-Cells; NK-Cells; PD-1; PD-L1